EP3924126A1 - Verfahren und vorrichtung zum bearbeiten von partikeln sowie nanopartikel eines pharmazeutischen wirkstoffs - Google Patents
Verfahren und vorrichtung zum bearbeiten von partikeln sowie nanopartikel eines pharmazeutischen wirkstoffsInfo
- Publication number
- EP3924126A1 EP3924126A1 EP20705334.9A EP20705334A EP3924126A1 EP 3924126 A1 EP3924126 A1 EP 3924126A1 EP 20705334 A EP20705334 A EP 20705334A EP 3924126 A1 EP3924126 A1 EP 3924126A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- analysis
- liquid jet
- particles
- liquid
- laser beams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002245 particle Substances 0.000 title claims abstract description 151
- 238000000034 method Methods 0.000 title claims abstract description 82
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 32
- 239000008186 active pharmaceutical agent Substances 0.000 title description 4
- 239000007788 liquid Substances 0.000 claims description 211
- 238000004458 analytical method Methods 0.000 claims description 132
- 238000005259 measurement Methods 0.000 claims description 35
- 238000012545 processing Methods 0.000 claims description 31
- 239000000725 suspension Substances 0.000 claims description 31
- 238000004108 freeze drying Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 238000011146 sterile filtration Methods 0.000 claims description 6
- 238000002441 X-ray diffraction Methods 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 230000006641 stabilisation Effects 0.000 claims description 3
- 238000011105 stabilization Methods 0.000 claims description 3
- 238000012371 Aseptic Filling Methods 0.000 claims description 2
- 238000000691 measurement method Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 description 23
- 238000003860 storage Methods 0.000 description 12
- 238000009826 distribution Methods 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000011109 contamination Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- UNBRKDKAWYKMIV-QWQRMKEZSA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CNC3=C1 UNBRKDKAWYKMIV-QWQRMKEZSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 190000008236 Carboplatin Chemical compound 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000001286 analytical centrifugation Methods 0.000 description 1
- -1 atalkropine Chemical compound 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229950004783 cipionate Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001405 ergometrine Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960001728 melarsoprol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000328 methylergometrine Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001420 photoelectron spectroscopy Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/02—Making metallic powder or suspensions thereof using physical processes
- B22F9/04—Making metallic powder or suspensions thereof using physical processes starting from solid material, e.g. by crushing, grinding or milling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
- B22F1/0545—Dispersions or suspensions of nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F2999/00—Aspects linked to processes or compositions used in powder metallurgy
Definitions
- the invention relates to a method for processing particles, in particular micro- and nanoparticles, in a suspension.
- the invention also relates to a device for processing such particles.
- the invention also relates to nanoparticles of a pharmaceutical active ingredient.
- Particles with sizes in the micro or nanometer range have a wide range of applications in a wide variety of areas of technology. The important thing here is the Manufacture of particles of certain sizes and
- Be size distributions The size, shape and / or
- Texture e.g. a surface or a
- the particles can also be important properties of the particles.
- colloid mills have been used to crush particles with sizes in the micro or nanometer range. Such mechanical
- Comminution devices are sometimes subject to high wear and tear, and their use also means that particles from the material of the mill get into the suspension. From EP 2 735 390 A1 the time shift is
- a beam of the aqueous medium with the particles is then irradiated by a second laser in order to fragment or comminute the particles.
- the invention is based on the object of providing a method and a device for efficient, in particular reproducible and in particular post-controllable processing, in particular comminuting, of particles in a liquid jet. Furthermore, the invention is based on the object of creating nanoparticles of a pharmaceutical active substance which are pollution-free and understandable
- this object is achieved by a method according to claim 1, a device according to claim 12 and nanoparticles according to claim 19.
- the method according to the invention relates in particular to the processing of particles in the
- the size of the particles can be less than 0.1 mm, in particular less than 0.01 mm, and more than 1 nm, in particular 500 nm.
- the size of the particles is in particular when to carry out the
- Particles comprises the steps: a) generating a jet of liquid.
- the particles are carried along with the liquid jet.
- the particles are in suspension in the liquid jet.
- the liquid jet can be in a
- Management structure such as a channel, pipe or
- the guide structure is transparent to the laser beam used, at least in sections.
- the liquid jet can but also be a freely falling jet of liquid.
- a freely falling liquid jet is to be understood as a liquid jet that is not guided. In particular, this releases a gravity (in particular
- the liquid jet can emerge from a jet generating device, for example a nozzle, which is used to generate the jet, without pressure or under pressure. With a liquid jet there is in particular a continuous one
- the irradiation by means of several laser beams from different directions serves as all areas in the cross section of the
- the laser is arranged on the
- the laser beams are directed onto the liquid jet in such a way that all sections of the cross section of the liquid jet are captured by the laser beams. This is further explained below in Described in detail. This means that all particles carried along can be processed with the laser beams in one pass.
- pulsed laser beams in particular pulse duration of the laser beams in the picosecond range
- Femtosecond range or nanosecond range can be used.
- the irradiation with the lasers serves to break up the particles.
- the irradiation runs without wear and, in contrast to mechanical processing or comminution, without contamination of the particles or the suspension.
- Wavelengths that interact sufficiently with the particles in order to efficiently shred them are particularly suitable. Also are high
- Wavelength of the laser beams can in particular, for example. 532 nm or 1030 nm or 515 nm or 343 nm, with several laser beams with
- Yb: YAG lasers can be used.
- the method according to the invention therefore provides that the suspension in which the particles are contained is analyzed. This analysis can be done before or after the irradiation.
- the Suspension before and after irradiation is analyzed.
- the analysis can be used to control the irradiation process.
- the storage of the analysis can be used to control the irradiation process.
- Irradiation is carried out beforehand, it can be checked whether the supplied particles have the appropriate initial size. It is also possible to determine the parameters of the irradiation in step b) based on the analysis results of the analysis before
- Analysis before and after the irradiation process can, for example, (also) be used to check whether there are any disturbances in the irradiation process
- Steps c) and d) can be provided alternatively or jointly.
- the particles can comprise inorganic material or consist of inorganic material.
- the material can be metal, for example gold or
- Such particles can be used, for example, as catalysts.
- the use of the method according to the invention or the use of the device according to the invention for processing can be used, for example, as catalysts.
- Particles that comprise pharmaceutical active ingredients in particular poorly water-soluble pharmaceutical active ingredients.
- Active ingredients that are suitable to be processed with the inventive method or. to be crushed are, for example. :
- Imipenem Chloramphenicol, Ciprofloxacin, Phenobarbital, Phenytoin, Metronidazole, Trimethoprim, Sulfamethoxazole, Linezolid, Paraaminosalicylic Acid, Amphotericin B,
- Methylergometrine fluphenazine, risperidone, clozapine, fluoxetine, carbamazepine, diazepam,
- Ketoconazole, fenofibrate, naproxen Ketoconazole, fenofibrate, naproxen.
- Nanoparticles an active pharmaceutical ingredient
- Liquid jet cross section is achieved by means of the laser from different directions, show.
- the analysis result (analysis step c)) is assigned to nanoparticles. This means that the
- nanoparticle there is nanoparticle, so that it is clearly identifiable which particles are or are described by the corresponding analysis. were “measured”. On the independent invention of the nanoparticles will be discussed in more detail below.
- Particles have a solubility in the liquid (the
- Suspension of less than 10 g / L, in particular less than 1 g / L, in particular a physiological solution can be provided as the liquid.
- the particles can be present in dispersed form.
- Starting state ie are or are dispersed in the liquid by means of an auxiliary before irradiation.
- an additive such as cellulose, hydroxyethyl cellulose, polyvinyl alcohol (PVA), sodium dodecyl sulfate (SDS), polyvinylpyrrolidone (PVP),
- Particle stabilization may be contained in the suspension.
- the presence of such an additive can also be found on the particles or. the suspension in which the particles are present.
- step b) For laser irradiation in step b) or. to form the laser arrangement in the corresponding device:
- the liquid jet in step b) is irradiated with at least three laser beams from different directions in each case. Through this the liquid jet is reliably the
- the (two, three or more) laser beams can run rotationally symmetrically with respect to the liquid jet.
- the laser beams are preferably pulsed
- a pulse repetition rate of the laser pulses is typically matched to the flow velocity of the liquid jet in such a way that all partial volumes of the liquid jet are hit by at least one laser pulse of all laser beams.
- the laser beams can flow in the direction of flow
- Hit liquid jet In particular, however, it can be provided that at least two laser beams, in particular all laser beams, in the flow direction of the liquid jet at the same height on the
- the laser beams hit the same point in flow direction, i.e. in a common area of impact, on the liquid jet. This increases the energy acting on the particles captured by the laser beams and ensures that no liquid volumes are caused by the fluid-mechanical influences of irradiation
- the individual pulses of the multiple laser beams preferably hit at the same time or at least substantially at the same time on the liquid jet.
- simultaneous impingement means that a time offset of the impingement of the pulses of the multiple laser beams is so small that the particles do not cover any significant distances in the flow direction of the liquid jet during this time interval. Distances that are smaller can be regarded as insignificant distances,
- the timing of the pulses can be based on the
- the flow velocity must be coordinated so that no liquid volume passes the area of impact without being irradiated by a laser pulse.
- the laser beams preferably run in a common plane which, in particular, is oriented perpendicular to the liquid jet. This can further increase the effectiveness of the processing. In particular, diffraction effects when the laser beams strike the liquid jet can be avoided or at least reduced.
- the laser beams are each inclined or, in particular, at right angles to the direction of flow
- Hit liquid jet Especially with At right angles, diffraction and / or reflection effects can be reduced or avoided.
- the liquid jet can in particular be directed at an angle to the flow direction that is smaller than or equal to the Brewster angle. It can be provided that depending on the type of radiation used and the optical
- the angle of incidence is selected at which the reflection when the laser beam hits the
- Liquid jet is minimized and when the laser beam passes through, the transmission at the phase boundary between the liquid jet and the surrounding air is minimized when exiting.
- the internal reflections of the phase boundary as much laser energy as possible can be held or in the liquid jet. can be used, while at the same time the reflection is minimized when entering.
- the particles can be comminuted (fragmented) in step b).
- inventive method or. its step b) can be carried out several times in order to obtain or even smaller particles. to their size distribution
- the pulse duration of the laser beams (in particular to bring about a comminution of the particles) can be in the picosecond range, ie at least one picosecond, in particular less than 100 picoseconds, in particular a few hundred
- the pulse duration can also be more than a nanosecond (short-pulsed and ultra-short-pulsed laser radiation).
- Picosecond range can be at least 500 nm, preferably at least 520 nm, particularly preferably at least 530 nm, and / or the wavelength of the laser beams can be at most 560 nm, preferably at most 540 nm, particularly preferably at most 535 nm.
- the wavelength of the laser beams can in particular, for example. 532 nm or 1030 nm or 515 nm or 343 nm, with multiple laser beams with different wavelengths
- Yb: YAG lasers can be used.
- the particles in step b) or. be remelted and / or fused in the device.
- Particles is at least a portion of the surface of the particles melted and it is after
- Solidification of the particles gives the particles a different shape and / or a different surface structure.
- the particles can be reshaped, especially to obtain particularly round (spherical) particles.
- targeted defects are also possible.
- Particles with special properties can be obtained. Particles can also be produced from hybrid materials. A chemical conversion of the particles can take place.
- the pulse duration of the laser beams can be
- nanosecond range i.e. be at least one nanosecond and less than one microsecond (short pulsed
- a wavelength of the laser beams (in particular for remelting or in particular with a pulse duration in the nanosecond range) can be at most 380 nm, preferably at most 360 nm, particularly preferably at most 350 nm, and / or the wavelength of the laser beams can be at least 310 nm, preferably
- the wavelength is
- the device can be designed in such a way that the laser beams in the area of incidence have a width which exceeds the diameter of the liquid jet. This also applies to the procedure.
- the device can, for example. one focusing device for each laser beam
- step c) or the analysis device and the analysis result have, via which the laser beam can be focused or. its width is adjustable.
- the analysis of the suspension includes in particular a
- Particle size can be determined. That is also conceivable
- Determination of the minimum particle size In particular, however, it is provided that a size distribution of the particles is measured.
- the device has a
- Analysis device comprises which is used to carry out a (in particular on-line or off-line) measurement by means of dynamic light scattering (DLS) or laser diffraction
- DLS dynamic light scattering
- the method can comprise a corresponding analysis step c).
- Light scattering allows measurements to be carried out in a short period of time, this method being particularly suitable for narrow size distributions, such as the one at hand
- the device has a
- Analysis device comprises which is used to carry out an offline measurement by means of an analytical disc centrifuge is trained.
- the method can comprise a corresponding analysis step c). This analysis can be used for the analysis of one or more modes
- Particle size distributions Particles with a tendency to agglomeration can also be measured with this method.
- the device has a
- the measurement can be carried out in-line, on-line or also off-line.
- the procedure can be a
- Deviations from a target value are recorded.
- Determination of the crystal structure of the particles is carried out or a corresponding analysis device can be provided in the device. It can in particular be provided that the crystal structure of the particles is determined or stored and / or compared with (for example with reference values, for example from previous measurements) on the basis of characteristic values obtained from the analysis.
- the corresponding measurement is typically carried out as an off-line measurement or the The analysis device is set up for an off-line measurement.
- the crystal structure of the particles is determined or stored and / or compared with (for example with reference values, for example from previous measurements) on the basis of characteristic values obtained from the analysis.
- the corresponding measurement is typically carried out as an off-line measurement or the The analysis device is set up for an off-line measurement.
- the analysis device is set up for an off-line measurement.
- the method can include a drying step preceding the analysis (e.g.
- the device comprises an analysis device which is used to carry out an on-line or in-line
- Spectroscopy measurement for example, spectroscopy in the UV, VIS, NIR or MIR range is conceivable), or it is provided that the method has a corresponding
- Analysis step c) comprises. This provides a fast analysis method by means of which the suspension can be analyzed directly. In particular, this variant does not require a sample to be taken, which then has to be disposed of, which makes the method more efficient.
- the device has a
- the procedure can be a
- the method can include a drying step preceding the analysis (e.g. spray drying or
- Freeze-drying step (lyophilization) or the device include a corresponding drying device.
- the device has a
- Analysis device comprises, which for performing an offline measurement by means of nuclear magnetic resonance spectroscopy (NMR spectroscopy), for example.
- NMR spectroscopy nuclear magnetic resonance spectroscopy
- Bonds of the particles is formed.
- the method can comprise a corresponding analysis step c).
- a chromatographic (in particular HPLC that is high-performance liquid chromatography) measurement is carried out within the framework of the method or the device comprises a correspondingly configured analysis device.
- the corresponding analysis device is typically designed to carry out an off-line measurement by means of high performance liquid chromatography (HPLC). It is also conceivable to use this analysis method as an in-line measurement, for example via a fluidic bypass, for example via the flow divider described in this application.
- HPLC high performance liquid chromatography
- Chromatographic separation can also be provided for purification or particle size selection.
- An in-line or on-line pH value and / or temperature measurement can also be provided.
- an analysis is carried out before and after the irradiation, by means of which the same measured variable (as already described above, e.g.
- Particle size distribution or crystal structure is recorded, in particular using the same measurement method.
- Liquid jet is separated in batches or
- an analysis result can be assigned to each batch as part of the method.
- the result of the analysis can be stored in a database.
- a database within the framework of the method, a
- the analysis is on-line and / or in-line Measurement includes. So that at least part of the liquid of the liquid jet is continuously analyzed or the liquid jet itself is analyzed in real time.
- the freely falling beam can be subjected to an analysis or measurement before or after the irradiation. It is also conceivable that the beam is captured and fed to an on-line measurement via a line.
- the liquid of the liquid jet can also before it reaches the jet generating device
- the analysis includes a batch measurement, in particular a batch measurement being carried out for each batch. This means that one measurement is carried out for each batch. This can be carried out “on-line” during the handling of the batch or "off-line” in such a way that in contrast to the on-line
- a "contactless” analysis method for example an optical measuring method
- an optical measuring method for example an optical measuring method
- the liquid of the liquid jet is divided into a main flow and a secondary flow.
- the secondary flow can be fed to the analysis device and the main flow can already be processed further. It is also conceivable that the secondary flow is mixed again with the main flow after the analysis.
- the division into a main stream and a secondary stream is particularly useful for
- the analysis results can be saved continuously in digital form.
- the method can compare newly determined analysis results with those that have already been determined, in particular in quasi real time
- Process parameters is made. For example, parameters of the laser radiation, such as the
- Pulse duration or intensity can be adjusted based on the calibration. It is conceivable, for example, that a certain maximum particle size is specified and
- Analysis results are continuously compared with this target variable and the parameters of the laser radiation are adjusted until the analysis results match the target variable.
- the analysis results can be stored in at least one blockchain within the scope of the invention. This enables forgery-proof continuous storage of the analysis results.
- the blockchain can be written on for a further batch.
- a blockchain is understood to mean a database whose integrity, i.e. Protection against subsequent manipulation by storing a hash value of a previous data record in the subsequent data record, i.e. by cryptographic
- Concatenation is secured. Exactly one blockchain can be provided. Several blockchains can also be provided. In particular, provision can be made for new data records to be created in the blockchain for each batch.
- the blockchain can be stored and processed in a distributed computing system.
- a central computing system can also be provided. Access rights to information from the blockchain can be configurable. Access to the blockchain can be restricted.
- a cryptographic key is used to provide a subscriber with the encrypted
- This encryption can be chosen so that it does not affect the headers in this case
- the method according to the invention is carried out on several corresponding devices and these devices each share their analysis results in a common
- Devices according to the invention can be designed to be networked with one another in such a way that they can write their analysis results in a common blockchain.
- the device according to the invention comprises:
- the jet generating device can for example be designed as a nozzle.
- Emitter generating device can be designed to be able to adjust the diameter of the liquid jet.
- Radiation generating device generates an unguided liquid jet.
- the device is preferably designed in such a way that the unguided liquid jet, in particular in a straight line, is generated in a freely falling manner.
- the laser arrangement is designed such that it is used for
- the laser beams can be pulsed.
- Laser arrangement can be designed in accordance with the statements made there.
- the laser arrangement is designed such that there are two
- Analysis device is designed and arranged in the device that the suspension of the liquid jet by means of the
- Analysis device can be analyzed. This analysis can be done before or after irradiation
- the analysis facility is for this purpose accordingly integrated into the device, e.g. Can be used via appropriate fluidic connections. It is also conceivable that an analysis can be carried out by means of the analysis device both before and after the irradiation.
- the analysis device can in each case comprise separate measuring devices for the analysis upstream and downstream of the irradiation or use the same measuring device for both analyzes.
- the device can further comprise an enclosure which is impermeable to the laser radiation of the laser beams.
- the housing surrounds an impact area of the
- the device can comprise a reflection housing.
- the reflection housing is particularly around the
- the reflection housing has a
- the surface facing the liquid jet is in particular designed and arranged in such a way that it emits laser radiation through the liquid jet
- E.g. can be the inner surface of the
- Reflection housing circular and concentric to Be formed arranged liquid jet. It can be provided that the reflection housing has several lenses (for example cylinder lenses) for coupling in the
- the lenses are typically arranged and designed in such a way that they further direct the laser beam onto the liquid jet in the same direction in which it strikes the lens.
- the reflective housing prevents
- Liquid jet emerges from the impingement area, which increases operational safety.
- better use is made of the laser radiation used, since radiation that has passed through the liquid jet is reflected back through the reflective housing and directed back onto the liquid jet.
- the device preferably also has at least one power measuring device for measuring a residual power of at least one of the laser beams on the other side of the liquid jet. From the remaining power (if the output power is known) the remaining power (if the output power is known).
- the degree of absorption when the laser beam hits or determine the laser beams on the liquid jet.
- the degree of absorption can be used to control the device for effective processing of the particles, for example for power regulation of the
- the laser arrangement is preferably designed in such a way that the laser beams run in a common plane.
- the plane can in particular be aligned perpendicular to the liquid jet.
- Laser arrangement can comprise at least two, preferably three, lasers (in the sense of laser beam sources). However, the laser arrangement can also have precisely one laser and one beam splitter device for generating the at least two laser beams and at least two
- the device is set up in such a way that all laser beams are designed in the same way.
- all laser beams preferably have the same wavelength.
- the light pulses of the laser beams hit the liquid jet preferably synchronously with one another.
- individual laser beams can be identical. Alternatively, at least one of the laser beams can have a different pulse energy.
- the device can be used for
- step b) Further training of step b) must be set up.
- the analysis device can be a
- Include particle size measuring device Of particular interest can be the maximum or minimal particle size or the size distribution of the particles before or after the irradiation.
- the analysis device can be a
- X-ray diffraction measuring device include. It can be of interest to characterize the crystal structure of the particles. In particular, it can be of interest to detect a change in the crystal structure. For this purpose, a corresponding measurement can be carried out before and after the irradiation and then the measurement results can be compared.
- the analysis device can further a
- chromatographic measuring device comprise chromatographic measuring device.
- the molecular structure of the particles can be of interest.
- it may be of interest to check whether the irradiation changes the
- the analysis device can be a measuring device for performing spectroscopic
- the analysis device can be a measuring device for performing a
- Particle size analysis e.g. using dynamic
- the analysis device can be a measuring device for carrying out crystal analysis (for example by means of X-ray diffraction) or a chromatographic measurement (for example HPLC).
- the device can be a flow divider device
- the flow divider device is designed to the liquid of the liquid jet in a
- the device can be set up in such a way that the secondary flow is fed to the analysis device.
- the secondary flow is merged or combined again with the main flow following the analysis. is mixed and the device has a corresponding line management.
- Such a flow divider device can be provided before and / or after the beam generating device.
- the device can further comprise a portioning device.
- a portioning device By means of the portioning device, it is possible, or the liquid jet. to portion its liquid in batches so that the individual batches are fluidically separated from one another.
- Portioning device can be coupled to the analysis and detection methods mentioned in such a way that automated portioning takes place as soon as the suspension and / or particle properties move outside of predetermined target values.
- the device comprises a filling device, by means of which one
- the device can also have a
- Identifying device comprise which one
- Liquid for example a batch or part of a batch
- a vessel for example, and a data record that contains analysis results for this amount of liquids.
- the device comprises a removal device which is designed to remove sample volumes of the liquid from the liquid jet.
- the removal device can be in
- Beam generating device be arranged.
- Removal device can, for example, for a
- the device comprises a sterile filtration device.
- Still filtration device enables aseptic filling of the liquid from the liquid jet into a vessel. It can be advantageous if the vessel
- the device can also comprise a spray drying or freeze drying device. This enables the particles present in suspension to be easily converted into powder form.
- a drying device into the device offers the advantage of a closed process chain in a single device. This can in particular reduce the risk of contamination during processing of the
- the method according to the invention can also comprise a sterile filtration step or a spray drying or freeze drying step.
- nanoparticles of a pharmaceutical active ingredient represent an independent part of the present invention.
- the nanoparticles were comminuted using steps a) and b) and analyzed using step c).
- the analysis result is available in a form that can be assigned to the nanoparticles. This can be used to provide evidence of quality, for example.
- the analysis result can be available locally alternatively, in particular additionally, also have been transmitted to an external database and stored there, e.g. to the database of an authority.
- the nanoparticles can be in the form of a batch that was fragmented under uniform process conditions in step b).
- the nanoparticles can be assigned a data record that includes the analysis result.
- the data record can be a characteristic of the irradiation in step b)
- the batch of nanoparticles can be in a mechanically manageable vessel.
- the vessel can be
- Identification features e.g. a QR code. This can simplify the assignment of the batch to the data record or the analysis result.
- the nanoparticles can be present in a suspension in an aqueous medium.
- the suspension can further comprise an additive for particle stabilization.
- an additive for particle stabilization In the context of the invention is in particular cellulose,
- Polyvinyl alcohol, polyvinylpyrrolidone (PVP), sodium dodecyl sulfate (SDS), polysorbate 80 or another surface and / or interface-active substance is provided as an additive, as already mentioned at the beginning.
- the type and / or concentration of the additive can be contained in the data set. This means that a manageable amount of nanoparticles is available, with the Properties of the suspension liquid as well as the
- Parameters for the production of the nanoparticles are available in a directly available and comprehensible form.
- the particles can also using a
- the powdery particles can then have been transferred to a vessel as described above.
- Fig. 1 shows a cross section through a
- Fig. 3 shows a laser arrangement with three lasers in the
- Fig. 4 shows a schematic representation of the impingement of the laser beams on the liquid jet when the particles are processed with the laser arrangement of FIG. 3;
- Fig. 5 is a flow chart of an inventive
- Fig. 6 shows a device according to the invention with two
- Fig. 7 shows a further laser arrangement with three lasers when processing particles in a liquid jet, in a schematic plan view
- FIG. 8 shows a further laser arrangement with three lasers during the processing of particles in a liquid jet, in a schematic plan view
- FIG. 9 a further flow diagram of a
- Fig. 10 is a schematic representation around a
- FIG. 11 a schematic representation around one
- Fig. 12 a schematic representation around one
- Fig. 13 shows a further laser arrangement with two lasers during the processing of particles in a liquid jet, in a schematic plan view
- Fig. 14 shows a further laser arrangement with a laser processing particles in a liquid jet, in a schematic plan view.
- Figure 1 shows a cross section through one
- Liquid jet 1 with particles (not shown) during processing with a single laser beam 2 according to the prior art according to EP 2 735 390 A1.
- the laser beam 2 detects the liquid jet 1 in its entire width coming from the beam direction.
- the laser radiation is, however, diffracted when it strikes the interface 3 between the liquid jet 1 and the environment 4 (air).
- sections 6 also arise within the cross section of the liquid jet 1, which cannot be reached by the laser beam 2. In these sections 6 not recorded
- Particles are therefore not hit by the laser radiation and cannot be processed.
- FIG. 2 shows a device 10 according to the invention for processing particles.
- the device 10 comprises a beam generating device 12 for generating a liquid jet 14 loaded with particles.
- the device 10 further comprises a laser arrangement 16 with two lasers 18a, 18b.
- the lasers 18a, 18b send pulsed
- Laser beams 20a, 2 Ob are from opposite directions on the laser beams 20a, 2 Ob.
- the laser beams 20a, 2 Ob are from opposite directions on the laser beams 20a, 2 Ob.
- Liquid jet 14 directed.
- the laser arrangement 16 and the beam generating device 12 are arranged overall within a housing 22.
- the housing 22 is impermeable to the laser radiation of the laser beams 20a, 2 Ob.
- the device 10 further comprises a first analysis device 23a and a second
- the beam generating device 12 comprises a
- Storage vessel 24 in which a liquid 26, here an aqueous liquid 26, is suspended therein
- a jet generating device 27 with a nozzle 28 is arranged on the storage vessel 24.
- the radiator generation device 27 or. Nozzle 28 lets the liquid 26 with the particles out of the Exit storage vessel 24 so that the
- Liquid jet 14 is created.
- the nozzle 28 works here without pressure (from the back pressure of the liquid in the
- Jet generating device 27 may be connected, which would allow the liquid 26 to emerge from the nozzle 28 under pressure. After exiting the nozzle 28, the falls
- Liquid surface geometries can lead to unwanted refractions of the laser radiation
- nozzle geometries can be provided in a slot shape.
- the liquid jet 14 with the processed particles reaches a collecting vessel 30.
- a liquid 32 with the processed particles suspended therein collects.
- the collecting vessel 30 can be vertical, for example. be spaced between 10 cm and 1 m.
- the storage vessel is 24
- Analysis device 23a or with the collecting vessel 30 via a further fluidic connection.
- Line 36 connected. This enables the analysis of the liquid 32 with the processed particles.
- the analysis device 23a also includes a
- Measuring device for performing measurements on
- Liquid jet 14 per se which is symbolically represented by the arrow with the reference symbol 33.
- the fluidic connection or. Line 34 connects the analysis device 23a in the present example with the storage vessel 24.
- the line 34 can, however, for example. also be connected directly to the beam generating device 28.
- Connecting analysis device 23a can alternatively, for example, also with a derivation 38 from the
- a discharge line 38 serves to discharge the liquid 32 from the collecting vessel 30.
- the discharge line 38 in the present example comprises a flow divider device 40, via which a secondary flow 42 can be separated from a main flow 44 of the liquid 32, which is discharged from the collecting vessel 30.
- this secondary stream 42 is fed to an analysis device 23b, which can be provided in the device 10 in addition or as an alternative to the analysis device 23a. After the liquid has been analyzed in the analysis device 23b, the
- Secondary stream 42 is fed back to main stream 44 and mixed with it.
- the main stream is then optionally one
- Filling device 48 for filling the suspension comprises a corresponding vessel 50.
- the vessel 50 has an identification feature 52, which in the present case is designed as a QR code.
- the collecting vessel 30 is also fluidically connected to a removal device 54. In the present case, it is possible to take samples manually using the removal device 54.
- the two lasers 18a, 18b of the laser arrangement 16 are shown in FIG.
- Flow direction of the liquid jet 14 is arranged.
- the laser beams 20a, 2 Ob meet in a common
- FIG. 3 shows an alternative laser arrangement 16 with three lasers 18a, 18b, 18c during the processing of
- the lasers 18a, 18b, 18c are here arranged rotationally symmetrically with respect to the liquid jet 14
- Laser beams 20a-20c run in a common horizontal plane 60 (the plane of the drawing) perpendicular to the liquid jet 14.
- focusing devices 62 which in the present example are designed as lens optics 62a, 62b, 62c, are provided for focusing the laser beams 20a-20c on the liquid jet 14.
- Figure 4 shows an enlarged representation of the
- FIG. 5 shows a flow chart of a method according to the invention for processing particles. The method can be carried out with the device 10 already described.
- a liquid jet 14 is generated, in which particles 38 are entrained.
- the liquid jet 14 is irradiated with several, preferably pulsed, laser beams 20a-20c from different directions.
- the particles 38 in the liquid jet 14 are processed by the laser beams 20a-20c.
- One of the laser arrangements 16 described above can be used for this purpose.
- a step 104 the suspension is analyzed after the irradiation by means of the laser beams 20a-20c.
- the result of the analysis is transmitted to a database 106, in which it is in a correspondingly treated or. crushed particles 56 assignable manner is stored.
- FIG. 6 shows a device 10 according to the invention for processing particles.
- the device 10 comprises a device 12 for generating a jet 14 of liquid loaded with particles.
- the device 10 further comprises a laser arrangement 16 with two lasers 18a, 18b.
- the lasers 18a, 18b send pulsed
- Laser beams 20a, 2 Ob are from opposite directions on the laser beams 20a, 2 Ob.
- the laser beams 20a, 2 Ob are from opposite directions on the laser beams 20a, 2 Ob.
- Liquid jet 14 directed.
- the laser arrangement 16 and the device 12 are, as in FIG. 2, arranged as a whole within an enclosure 22.
- the device 12 comprises a storage vessel 24 in which a liquid 26, here an aqueous liquid 26, with particles (not shown) suspended therein is stored. On the storage vessel 24 is one
- the nozzle 28 works here without pressure but can also be operated under pressure. After exiting the nozzle 28, the liquid jet 14 falls freely (unguided) under the influence of gravity.
- the liquid jet 14 with the processed particles reaches a collecting vessel 30.
- a liquid 32 with the processed particles suspended therein collects. See also figure 2.
- FIG. 3 shows a laser arrangement 16 with three lasers 18a, 18b, 18c, similar to FIG. 3.
- This laser arrangement 16 could be used in the device 10 according to FIG. 2 or 6 instead of the laser arrangement 16 shown there.
- the laser beams 20a-20c run here in a common horizontal plane 40 (the plane of the drawing) perpendicular to the liquid jet 14 and are
- a power measuring device 68a, 68b, 68c is arranged for each of the lasers 18a-18c.
- the power measuring devices 68a-68c determine the remaining powers of the respective ones
- Figure 5 shows a laser arrangement 16 for a
- Liquid jet 14 are carried along.
- the laser assembly 16 includes a
- the Beam splitter device 72 divides the laser radiation emitted by the laser 18 into three separate laser beams 20a, 20b, 20c.
- the laser assembly 16 further includes three
- Light guide devices 70a, 7 Ob, 70c The
- Light guide devices 70a-70c guide the laser beams 20a-20c to the liquid jet 14. Die
- Light guide devices 70a-70c are here as
- Light guide devices 70a-70c may be provided. In the embodiment according to FIG. 5 will be the
- Particles 56 by the laser beams 2 Oa-20c are remelted (melted) and fused.
- a wavelength of the laser beams 2 Oa-20c is 343 nm here.
- the pulse repetition rate of the laser beams 2 Oa-20c may be 100 Hz or more.
- a pulse duration of the light emission can be 10 nanoseconds.
- the laser beams 20a-20c can each have a fluence of at least 0.5 J / cm2.
- the aqueous liquid 26 can be a
- the particles 38 can consist of gold or platinum.
- FIG. 9 shows a flow chart of a method according to the invention for processing particles. The method can be carried out with the devices 10 described above
- a liquid jet 14 is generated, in which particles 38 are entrained.
- a device 12 according to FIG. 2 can be used for this purpose.
- the liquid jet 14 is irradiated with several, preferably pulsed, laser beams 20a-20c from different directions.
- the particles 38 in the liquid jet 14 are processed by the laser beams 20a-20c.
- One of the above-described laser arrangements 16 are processed by the laser beams 20a-20c.
- a liquid jet 14 is generated, in which particles 38 are entrained.
- the liquid jet 14 is irradiated with several, preferably pulsed, laser beams 20a-20c from different directions.
- the particles 38 in the liquid jet 14 are processed by the laser beams 20a-20c.
- One of the laser arrangements 16 described above can be used for this purpose.
- a step 103 the liquid 32 (with processed particles) of the liquid jet 14 is collected in a collecting vessel 30.
- FIGS 10, 11 and 12 illustrate the use of a
- the device 10 can,
- a reflection housing 74 in particular in the area of the impact area 55, comprise a reflection housing 74.
- the arrangement of a reflective housing 74 is around the
- the reflection housing 74 is in particular around the
- the reflection housing 74 has a reflective inner one, that is to say it faces the liquid jet
- the (inner, the liquid jet facing) surface 78 is in particular designed and arranged such that it reflects laser radiation that passes through the liquid jet 14 back into the liquid jet 14.
- the inner surface 78 of the reflective housing 74 can be
- the reflective housing 74 has a plurality of lenses 80 (e.g.
- the lenses 80 are typically of this type
- the reflection on the inner surface 78 is in each case by corresponding in FIGS. 10 to 12
- FIG. 12 A variant is shown in which three laser beams 20a, 2 Ob and 20c in one plane through corresponding lenses 80a, 8 Ob and 80c
- Reflection housing 74 are coupled in and strike the liquid jet 14 there and are correspondingly reflected on the inner surface 78 of the reflection housing 74.
- the coupling does not necessarily have to take place via lenses 80. It can also be provided that the
- Laser beams 20 are guided onto the beam 14 at an angle that runs obliquely to the direction of flow 76, so that, as shown in FIG. 13, they can be guided into the reflection housing 74 from below or from above, for example.
- the lasers 20 of the laser arrangement or when carrying out the method can in particular be directed at an angle to the flow direction 76 of the liquid jet 14 which is smaller than or equal to the Brewster angle.
- Brewster's angle is represented by line 84 in FIG. It can be provided that depending on the type of radiation used and the optical properties of the phase boundaries between
- Angle of incidence 86 is selected at which the
- FIG. 14 a further laser is provided which radiates onto the liquid jet 14 from a different direction, but this is not shown.
- step b) is irradiated with at least three, in particular pulsed, laser beams from respectively different directions.
- the laser beams are rotationally symmetrical with respect to the liquid jet.
- the direction of flow of the liquid jet hit the liquid jet at the same height. 5.
- the method according to any one of the preceding aspects characterized in that the laser beams run in a common plane.
- a wavelength of the laser beams is at least 500 nm, preferably at least 520 nm,
- the wavelength of the laser beams is at most 560 nm, preferably at most 540 nm, particularly preferably
- the wavelength of the laser beams is 532 nm.
- Nano-second range 11. The method according to one of aspects 9 or 10, characterized in that a wavelength of the laser beams is at most 380 nm, preferably at most 360 nm, particularly preferably at most 350 nm, and / or that the wavelength of the laser beams is at least 310 nm,
- the wavelength of the laser beams is 343 nm.
- a laser arrangement for generating at least two, in particular pulsed, laser beams
- the laser arrangement is set up to generate the at least two laser beams from in each case
- the device according to aspect 13 further comprising a housing which is impermeable to the laser radiation of the laser beams and which has an impact area of the
- the laser arrangement comprises at least two, preferably three, lasers. 16.
- the laser arrangement has exactly one laser, one beam splitter device for generating the at least two laser beams and at least two
- Power measuring device for measuring a residual power of at least one of the laser beams beyond the
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019201781.9A DE102019201781A1 (de) | 2019-02-12 | 2019-02-12 | Verfahren und Vorrichtung zum Bearbeiten von Partikeln |
DE102020101164.4A DE102020101164A1 (de) | 2020-01-20 | 2020-01-20 | Verfahren und Vorrichtung zum Bearbeiten von Partikeln sowie Nanopartikel eines pharmazeutischen Wirkstoffs |
PCT/EP2020/053553 WO2020165220A1 (de) | 2019-02-12 | 2020-02-12 | Verfahren und vorrichtung zum bearbeiten von partikeln sowie nanopartikel eines pharmazeutischen wirkstoffs |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3924126A1 true EP3924126A1 (de) | 2021-12-22 |
Family
ID=69591632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20705334.9A Withdrawn EP3924126A1 (de) | 2019-02-12 | 2020-02-12 | Verfahren und vorrichtung zum bearbeiten von partikeln sowie nanopartikel eines pharmazeutischen wirkstoffs |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220118090A1 (de) |
EP (1) | EP3924126A1 (de) |
CN (1) | CN113597352A (de) |
WO (1) | WO2020165220A1 (de) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014964A (en) * | 1975-07-16 | 1977-03-29 | Federal-Mogul Corporation | Process for making metal powder using a laser |
JPWO2004110405A1 (ja) * | 2003-06-11 | 2006-08-17 | 株式会社奈良機械製作所 | 薬物ナノ粒子、その粒子を使用した薬剤の製造方法および薬剤の製造装置 |
US8246714B2 (en) * | 2009-01-30 | 2012-08-21 | Imra America, Inc. | Production of metal and metal-alloy nanoparticles with high repetition rate ultrafast pulsed laser ablation in liquids |
US8992815B2 (en) * | 2010-02-10 | 2015-03-31 | Imra America, Inc. | Production of organic compound nanoparticles with high repetition rate ultrafast pulsed laser ablation in liquids |
WO2011150420A1 (en) * | 2010-05-28 | 2011-12-01 | Baylor College Of Medicine | Modified gold nanoparticles for therapy |
EP2735389A1 (de) * | 2012-11-23 | 2014-05-28 | Universität Duisburg-Essen | Verfahren zur Herstellung reiner, insbesondere kohlenstofffreier Nanopartikel |
-
2020
- 2020-02-12 EP EP20705334.9A patent/EP3924126A1/de not_active Withdrawn
- 2020-02-12 US US17/430,451 patent/US20220118090A1/en active Pending
- 2020-02-12 CN CN202080021120.3A patent/CN113597352A/zh active Pending
- 2020-02-12 WO PCT/EP2020/053553 patent/WO2020165220A1/de unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020165220A1 (de) | 2020-08-20 |
CN113597352A (zh) | 2021-11-02 |
US20220118090A1 (en) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1372552B1 (de) | Vorrichtung zur bearbeitung und diagnose von augengewebe | |
DE102007028042B3 (de) | Verfahren zur Laserbearbeitung transparenter Materialien | |
EP2629079B1 (de) | Verfahren und Vorrichtungen zur Präparation mikroskopischer Proben mit Hilfe von gepulstem Licht | |
EP0758447B1 (de) | Verfahren und vorrichtung zur bestimmung von elementzusammensetzungen und -konzentrationen | |
EP3974804A1 (de) | Verfahren zur erfassung der konzentration von organischen partikeln in der luft sowie vorrichtung hierfür | |
DE112011100502T5 (de) | Produktion organischer verbundnanopartikel mit ultraschneller gepulster laserablation mit hoher wiederholungsrate in flüssigkeiten | |
DE102013009962B3 (de) | LIBS-Messtubus | |
DE102018128377A1 (de) | Verfahren und Vorrichtung zur Überwachung eines Schweißprozesses zum Verschweißen von Werkstücken aus Glas | |
DE4104316A1 (de) | Probenaufnahme fuer spektralphotometer | |
DE102015207834A1 (de) | Bearbeitungsmaschine für ein mit einem Laserstrahl durchzuführendes Produktionsverfahren und Verfahren zu deren Betrieb | |
DE102020120199A1 (de) | Verfahren zur Erfassung der Konzentration von organischen Partikeln in der Luft sowie Sensor hierfür | |
EP3924126A1 (de) | Verfahren und vorrichtung zum bearbeiten von partikeln sowie nanopartikel eines pharmazeutischen wirkstoffs | |
DE102020101164A1 (de) | Verfahren und Vorrichtung zum Bearbeiten von Partikeln sowie Nanopartikel eines pharmazeutischen Wirkstoffs | |
DE102014117613B4 (de) | Laseranordnung und Verfahren zur Untersuchung eines Objektes | |
WO2018189080A1 (de) | Vorrichtung und verfahren zum laserbasierten trennen eines transparenten, sprödbrechenden werkstückes | |
EP2477568B1 (de) | Laserstrahl-ausrichteinheit und laserbearbeitungsgerät zur bearbeitung eines materials | |
DE102008035898A1 (de) | Vorrichtung und Verfahren zur Specklereduktion im Bereich der Laseranwendungen | |
DE10148783B4 (de) | Verfahren zur nicht-invasiven optischen Bearbeitung von Geweben des Auges sowie zu dessen Diagnose und Vorrichtung zur Durchführung dieser Verfahren | |
EP2805147B1 (de) | Vorrichtung zum kalibrieren eines streulichtmessgerätes | |
DE102011107982A1 (de) | Werkzeugkopf (LCP-Kopf) | |
DE10218415A1 (de) | Partikeluntersuchungsgerät | |
EP3394611B1 (de) | Verfahren zur analyse eines probenmaterials | |
DE102012024883B3 (de) | Vorrichtung und Verfahren zum Messen der Änderung der Intensität eines Probepulses bei Durchgang durch ein Medium | |
DE102008048342A1 (de) | SERS-Substrat, Verfahren zu seiner Herstellung und Verfahren zum Detektieren eines Analyten mittels SERS | |
EP1924829B1 (de) | Verfahren und vorrichtung zum erfassen der randfeldintensität eines laserstrahls |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210907 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20240229 |